CHIME applauds CMS recommendation for 90-day reporting period

Cara Livernois | | Health Exec | Economics

After the announcement of the recommendation of the 90-day reporting period by the Centers for Medicare & Medicaid Services, the College of Healthcare Information Management Executives (CHIME) has offered its support of the decision.

The 90-day reporting period, shortened from a full year, allows for healthcare organizations to more rapidly implement the technological systems that are needed to provide better quality of care and supporting new methods of payment, according to CHIME.

“We are pleased that the today recommended a 90-day reporting period in 2016 for hospitals in the Meaningful Use program,” stated CHIME Board Chair Marc Probst and CHIME President and CEO Russell Branzell.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.